Chemomab Therapeutics Ltd.
For the period ended Dec 31, 2025. Filed Mar 23, 2026.
View on SEC.govAbout this filing
The yearly report of a company based outside the US. It covers much of what a 10-K does, and may follow accounting rules other than US ones.
FY2025 · Filed Mar 23, 2026
Contents
Cover page
Show cover page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 20-F
(Mark One)
☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31,2025
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
OR
☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring this shell company report
Commission File Number 001-40490
Chemomab Therapeutics Ltd.
(Exact name of Registrant as specified in its charter)
Not Applicable
(Translation of Registrant’s name into English)
State of Israel
(Jurisdiction of incorporation or organization)
10 Habarzel Street, Building C, 10th Floor, Tel Aviv 6158101, Israel
Telephone+972 77-331-0156
(Address of principal executive offices)
Sigal Fattal
Chief Financial Officer
10 Habarzel Street, Building C, 10th Floor
Tel Aviv, Israel
Telephone+972 77-331-0156
(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)
Securities registered or to be registered, pursuant to Section 12(b) of the Act
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| American Depositary Shares, each representing eighty (80) ordinary shares, no par value per share | CMMB | Nasdaq Capital Market |
| Ordinary shares, no par-value* | NA | Nasdaq Capital Market |
*Not for trading; only in connection with the registration of American Depository Shares.
Securities registered or to be registered pursuant to Section 12(g) of the Act: None
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None
Indicate the number of outstanding shares of each of the issuer’s classes of capital stock or common stock as of the close of the period covered by the annual report. As of December 31, 2025, the registrant had outstanding 575,381,320 ordinary shares, no par value (equal to 7,192,276 ADSs).
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes☐ No ☒
If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Yes☐ No ☒
Note-Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| ☐ Large accelerated filer | ☐ Accelerated filer | ☒ Non-accelerated filer | ☐ Emerging growth company |
|---|
If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.☐
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐
Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:
| ☒ U.S. GAAP | ☐ International Financial Reporting Standards as issued by the International Accounting Standards Board | ☐ Other |
|---|
If “Other” has been checked in response to the previous question indicate by check mark which financial statement item the registrant has elected to follow.
Item 17☐ Item 18 ☐
If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes☐ No☒
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.
Yes☐ No☒
| CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS | 2 | |
|---|---|---|
| PRESENTATION OF FINANCIAL AND OTHER INFORMATION | 4 | |
| PART I | 5 | |
| ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS | 5 | |
| ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE | 5 | |
| ITEM 3. KEY INFORMATION | 5 | |
| A. | [Reserved.] | 5 |
| B. | Capitalization and Indebtedness | 5 |
| C. | Reasons for the Offer and Use of Proceeds | 5 |
| D. | Risk Factors | 5 |
| ITEM 4. INFORMATION ON THE COMPANY | 27 | |
| A. | History and Development of the Company | 27 |
| B. | Business Overview | 28 |
| C. | Organizational Structure | |
| D. | Property, Plants and Equipment | |
| ITEM 4A. UNRESOLVED STAFF COMMENTS | 64 | |
| ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS | 64 | |
| A. | Operating Results | 65 |
| B. | Liquidity and Capital Resources | 69 |
| C. | Research and Development, Patents and Licenses, Etc. | 71 |
| D. | Trend Information | 71 |
| E. | Critical Accounting Estimates | 71 |
| ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES | 71 | |
|---|---|---|
| A. | Directors and Senior Management | 71 |
| B. | Compensation | 73 |
| C. | Board Practices | 77 |
| D. | Employees | 86 |
| E. | Share Ownership | 86 |
| F. | Disclosure of a Registrant’s Action to Recover Erroneously Awarded Compensation | 86 |
| ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS | 86 | |
| A. | Major Shareholders | 86 |
| B. | Related Party Transactions | 88 |
| C. | Interests of Experts and Counsel | 88 |
| ITEM 8. FINANCIAL INFORMATION | 88 | |
| A. | Consolidated Statements and Other Financial Information | 88 |
| B. | Significant Changes | 89 |
| ITEM 9. THE OFFER AND LISTING | 89 | |
| A. | Offer and Listing Details | 89 |
| B. | Plan of Distribution | 89 |
| C. | Markets | 89 |
| D. | Selling Shareholders | 89 |
| E. | Dilution | 89 |
| F. | Expenses of the Issue | 89 |
| ITEM 10. ADDITIONAL INFORMATION | 89 | |
| A. | Share Capital | 89 |
| B. | Memorandum and Articles of Association | 89 |
| C. | Material Contracts | 90 |
| D. | Exchange Controls | 90 |
| E. | Taxation | 98 |
| F. | Dividends and Paying Agents | 98 |
| G. | Statement by Experts | 98 |
| H. | Documents on Display | 98 |
| I. | Subsidiary Information | 99 |
| ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK | 99 |
|---|---|
| ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES | 99 |
| PART II | 105 |
| ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES | 105 |
| ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS | 105 |
| ITEM 15. CONTROLS AND PROCEDURES | 105 |
| ITEM 16. [RESERVED] | 106 |
| ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT | 106 |
| ITEM 16B. CODE OF ETHICS | 106 |
| ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES | 107 |
| ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES | 107 |
| ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS | 107 |
| ITEM 16F. CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANT | 107 |
| ITEM 16G. CORPORATE GOVERNANCE | 107 |
| ITEM 16H. MINE SAFETY DISCLOSURE | 108 |
| ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS | 108 |
| ITEM 16J. INSIDER TRADING POLICY | 109 |
| ITEM 16K. CYBERSECURITY | 109 |
| PART III | 110 |
| ITEM 17. FINANCIAL STATEMENTS | 110 |
| ITEM 18. FINANCIAL STATEMENTS | 110 |
| ITEM 19. EXHIBITS | 110 |
| SIGNATURES | 112 |
| INDEX | F-1 |
INTRODUCTION
In this Annual Report on Form 20-F (the “Annual Report”), unless context otherwise requires:
| • | references to “Chemomab Therapeutics Ltd.”, “Chemomab,” the “Company,” “us,” “we” and “our” refer to Chemomab Therapeutics Ltd., an Israeli company and its consolidated subsidiaries; however, with respect to the presentation of financial results for historical periods that preceded the Merger (as defined below), these terms refer to the financial results of the Company’s wholly owned subsidiary, Chemomab Ltd., which was the accounting acquirer in the Merger; |
|---|
| • | references to “ordinary shares,” “our shares” and similar expressions refer to the Company’s ordinary shares, no nominal (par) value; |
|---|
| • | references to “ADS” refer to the American Depositary Shares listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “CMMB,” each representing eighty (80) ordinary shares; |
|---|
| • | references to “dollars,” “U.S. dollars” and “$” are to United States Dollars; |
|---|
| • | references to “NIS” are to New Israeli Shekels; |
|---|
| • | references to the “Companies Law” are to Israel’s Companies Law, 5759-1999, as amended; |
|---|
| • | references to the “SEC” are to the U.S. Securities and Exchange Commission; and |
|---|
| • | references to the “Merger” refer to the merger involving Anchiano Therapeutics Ltd., or Anchiano, and Chemomab Ltd., whereby a wholly owned subsidiary of Anchiano merged with and into Chemomab Ltd., with Chemomab Ltd. surviving as a wholly owned subsidiary of Anchiano. Upon consummation of the Merger on March 16, 2021, Anchiano changed its name to “Chemomab Therapeutics Ltd.” and the business conducted by Chemomab Ltd. became primarily the business conducted by the Company. |
|---|
This Annual Report contains estimates, projections and other information concerning our industry and our business, as well as data regarding market research, estimates and forecasts prepared by our management. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those discussed under the headings “Special Note Regarding Forward-Looking Statements” and Item 3.D. “Risk Factors” in this Annual Report.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.